RT Journal Article SR Electronic T1 Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7) JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 1636 OP 1641 DO 10.1097/IGC.0000000000000831 VO 26 IS 9 A1 Philipp Harter A1 Jalid Sehouli A1 Alexander Reuss A1 Klaus Baumann A1 Lars Hanker A1 Rainer Kimmig A1 Willibald Schröder A1 Alexander Burges A1 Martina Gropp-Meier A1 Christian Kurzeder A1 Sven Mahner A1 Ulrich Canzler A1 Hans-Joachim Lück A1 Werner Meier A1 Tanja Fehm A1 Andreas du Bois YR 2016 UL http://ijgc.bmj.com/content/26/9/1636.abstract AB Background Gynecologic sarcomas are rare diseases with still undefined optimal treatment. Platinum and anthracyclines were reported as active agents in gynecologic sarcoma and carcinosarcoma. So far, data regarding the combination of carboplatin and pegylated liposomal doxorubicin for this patient population are missing.Methods This prospective single-arm multicenter phase II trial evaluated the efficacy of carboplatin AUC 6 in combination with pegylated liposomal doxorubicin 40 mg/m2 q28 in 40 patients with newly diagnosed or recurrent gynecologic sarcoma or carcinosarcoma.Results Twenty patients with carcinosarcoma and 20 patients with leiomyosarcoma or endometrial stromal sarcoma were included. The percentage of patients with grade 3/4 neutropenia was 50%, but we did not observe any febrile neutropenia. The rates of grade 1 and 2 palmo-plantar erythema were moderate with 25% and 10%, respectively. Response rate was 33.3%. The 12-month progression-free and overall survival times were 32.5% and 77.0%, respectively.Conclusions The combination of carboplatin and pegylated liposomal doxorubicin is feasible and has activity within the investigated study cohort.